The application of an extracellular vesicle-based biosensor in early diagnosis and prediction of chemoresponsiveness in ovarian cancer Meshach Asare-Werehene^{1,2}, Rob Hunter^{4,5}, Emma Gerber^{1,2}, Arkadiy Reunov³, Isaiah Brine⁴,

5 Chia-Yu Chang^{6,7,8}, Chia-Ching Chang^{6,7,8}, Dar-Bin Shieh^{9,10}, Dylan Burger², *Hanan
6 Anis⁵ and *Benjamin K. Tsang^{1,2}

- 7
- 8 ¹Departments of Obstetrics & Gynecology and Cellular & Molecular Medicine, Centre for Infection, Immunity and
- 9 Inflammation, Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
- 10 ²Chronic Disease Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON K1Y 4E9, Canada
- ³St. Francis Xavier University, Department of Biology, 2320 Notre Dame Avenue, Antigonish, NS, B2G 2W5,
 Canada
- ⁴Ottawa-Carleton Institute for Biomedical Engineering, University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada
- ⁵School of Electrical Engineering and Computer Science, University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada
- ⁶Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan
 30068
- ⁷Center for Intelligent Drug Systems and Smart Bio-devices (IDS²B), National Yang Ming Chiao Tung University,
 Hsinchu, Taiwan, 30068
- ⁸Department of Electrophysics, National Yang Ming Chiao Tung University, Hsinchu, Taiwan, 30010
- ⁹ Institute of Physics, Academia Sinica, Taipei, Taiwan 10529
- ²¹¹⁰Institute of Basic Medical Science, Institute of Oral Medicine and Department of Stomatology, National Cheng
- 22 Kung University Hospital, National Cheng Kung University, Tainan 704, Taiwan.

23	¹¹ Advanced Optoelectronic	Technology	Center	and	Center	for	Micro/Nano	Science	and	Technology,	National
24	Cheng Kung University, Tai	nan 701, Taiv	wan								

25

Running Title: Extracellular vesicle-mediated CDDP secretion in OVCA chemoresistance 26 27 *Correspondance: Dr. Benjamin K Tsang, Chronic Disease Program, Ottawa Hospital Research Institute, The 28 Ottawa Hospital (General Campus), Ottawa, Canada K1H 8L6; 29 Tel: 1-613-798-5555 ext 30 72926; Email: btsang@ohri.ca 31 Dr. Hanan Anis, School of Electrical Engineering and Computer Science, University of Ottawa, 32 Ottawa, Ontario, K1N 6N5, Canada; Tel: Email: hanis@uottawa.ca 33

34

35

Author Contributions: M.A.W., B.K.T., R.H. and H.A. conceived and designed the study. 36 M.A.W. performed all cellular and molecular biology experiments unless otherwise stated. R.H. 37 38 I.B. and H.A designed biosensor and performed SERS analyses. M.A.W, E.G. and D.B. performed NTA analyses. A.R. performed electron microscopy analyses. D.S. performed energy 39 40 dispersive X-ray spectroscopy and inductively coupled plasma reactive ion etching. C.Y.C and 41 C.C.C. designed and provided human recombiant pGSN. Patient-derived EV isolation and Western blot was done by E.G. M.A.W. analysed the data and wrote the paper with scientific 42 43 input and feedback from all authors.

45

46 **Competing Interests:** The authors declared no conflicts of interest.

47

48 ABSTRACT

Ovarian cancer (OVCA) is the most fatal gynecological cancer with late diagnosis and 49 50 chemoresistance being the main obstacles of treatment success. Since there is no reliable 51 approach to diagnosing patients at an early stage as well as predicting chemoresponsiveness, 52 there is the urgent need to develop a diagnostic platform for such purposes. Extracellular vesicles (EVs) present as an attractive biomarker given their potential specificity and sensitivity to tumor 53 54 sites. We have developed a novel sensor which utilizes cysteine functionalized gold 55 nanoparticles to simultaneously bind to cisplatin (CDDP) and EVs affording us the advantage of predicting OVCA chemoresponsiveness, histologic subtypes, and early diagnosis using surface 56 enhanced Raman spectroscopy. EVs were isolated and characterized from chemosensitive and 57 resistant OVCA cells lines as well as pre-operative patient blood samples. The mechanistic role 58 59 of plasma gelsolin (pGSN) in EV-mediated CDDP secretion in OVCA chemoresistance was 60 investigated using standard cellular and molecular techniques. We determined that chemoresistant cells secrete significantly higher levels of small EVs (sEVs) and EVs containing 61 62 CDDP (sEV-CDDP) compared with their sensitive counterparts. pGSN interacted with cortactin (CTTN) and both markers were significantly upregulated in chemoresistant patients' tumors 63 compared with the sensitive patients. Silencing pGSN decreased EV and EV-CDDP secretions in 64 the resistant cells whereas its over-expression in sensitive cells upregulated EV and EV-CDDP 65 secretion, suggesting the potential role of pGSN in EV-mediated CDDP export. sEV/CA125 66

67 ratio outperformed CA125 and sEV individually in predicting early stage, chemoresistance, 68 residual disease, tumor recurrence, and patient survival. These findings highlight pGSN as a 69 potential therapeutic target as well as providing a potential diagnostic platform to detect OVCA 70 earlier and predict chemoresistance; an intervention that will positively impact patients' survival.

71 **INTRODUCTION**

72 Ovarian cancer (OVCA) remains the most fatal gynecological cancer with a 5-year survival rate of 45% primarily due to late diagnosis and chemoresistance (1-3). Although patients initially 73 74 respond to treatment (primary surgical debulking and chemotherapy), about 50 - 70% of the patients relapse and become resistant to further treatment (3). The 5-year survival rate for stage 1 75 patients is >90% whereas that for stage 2, 3 and 4 are \sim 70%, \sim 39%, and \sim 17% respectively (1, 76 77 3). However, only about 19% of ovarian cancer patients are diagnosed at the early stage despite the use of conventional biomarkers such as CA125, HE4, ROMA, and OVA1 (1-6). This 78 suggests the urgent need for highly reliable and effective diagnostic platforms for early stage 79 80 disease and chemoresistant prediction.

81 Plasma gelsolin (pGSN; also known as secreted GSN) is a multi-functional actin binding protein 82 and the secreted isoform of the GSN gene (7-9). pGSN is implicated in the progression, chemoresistance, and metastasis of a plethora of cancer types including OVCA (10-18). We have 83 84 previous demonstrated that pGSN is highly expressed in chemoresistant OVCA tumors and also transported via small extracellular vesicles (sEVs) (10, 15, 16). sEV-pGSN autoregulates its own 85 gene expression and confers resistance to chemosensitive cells in a paracrine manner through the 86 activation of the FAK/AKT/HIF1a pathway (10). Additionally, sEV-pGSN induces caspase-3 87 dependent apoptosis as well as suppresses the anti-tumor functions of immune cells such as 88

CD8+ T cells, CD4+ T cells, and M1 macrophages (15, 16). Although pGSN is closely
associated with sEV secretion, we have yet to determine the role of pGSN in sEV secretion.

EVs present as an attractive biomarker given they carry bioprints of the secreting cells and could 91 92 capture the molecular landscape of cancer cells. This offers a superior advantage for cancer 93 diagnostic tests compared with other biomarkers. EVs are secreted from most cells and are also 94 present in liquid biopsies such as urine, plasma, and ascites. EVs are broadly categorized into apoptotic bodies (>1000 nm), large EVs (200 – 500 nm) and small EVs (30 – 300 nm) and serve 95 as carriers for transporting molecular signatures such as proteins, RNA, DNA, and miRNAs (19, 96 97 20). The contents of the cargo could induce phenotypic and genetic changes in the recipient cells. 98 sEVs play a key role in tumorigenesis and chemoresistance in different cancer types (15, 21-23). 99 Chemoresistant OVCA cells secrete increased levels of sEVs containing pGSN which confers chemoresistance on otherwise chemosensitive cells as well as downregulate the tumor-killing 100 101 functions of immune cells in the tumor microenvironment (10, 15, 16). Despite the potential 102 diagnostic utility of sEVs, detecting EV specific antigens using conventional techniques like 103 polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) present as a 104 major obstacle in cancer diagnostics. Thus, the use of technologies that could effectively detect 105 the biochemical fingerprints of EVs will significantly enhance their clinical utility as opposed to 106 targeting specific markers.

107 Surface enhanced Raman spectroscopy (SERS) has the capacity to examine the biochemical 108 structure of biological analytes and presents as a useful tool in differentiating cancer cells from 109 normal cells (24, 25). Interestingly, the application of SERS in liquid biopsy analyses has 110 encountered major setbacks due to the heterogeneity of samples and interferences from large 111 proteins. Similar obstacles are likely to be encountered in chemoresistance prediction given that

not all circulating EVs originate from cancer cells, and those share biochemical characteristics with the target EVs. We have recently developed a novel sensor which utilizes cysteine functionalized gold nanoparticles to simultaneously bind to cisplatin (CDDP) and EVs affording us the advantage of quantifying EVs and EV-CDDP with high accuracy using SERS (26). This unique biosensor will enable us to overcome the challenges of tumor heterogeneity and protein interferences.

In this study, we investigated the application of an EV-based novel biosensor in the diagnosis of early-stage OVCA and the prediction of chemoresistance. Additionally, we examined the regulation of EV-mediated CDDP efflux by pGSN in chemoresistant OVCA cells. We found that pGSN is a key regulator of EV secretion and EV-mediated release of CDDP from chemoresistant OVCA cells. sEV/CA125 is also a strong indicator for stage 1 OVCA as well as predictor of chemoresistance.

124

125 MATERIALS AND METHODS

126 **Ethics Statement**

All the subjects recruited provided a written informed consent and the study was conducted in
accordance with the appropriate guidelines approved by the Centre hospitalier de l'Université de
Montreal (CHUM) Ethics Committee (IRB approval number; BD 04-002) and the Ottawa Health
Science Network Research Ethics Board (IRB approval number; OHSN-REB 20150646-01H).

132 Plasma Samples:

133 Ninety-nine (99) ovarian cancer patients (high grade serous, HGS; 69, low grade serous, LGS; 4, 134 not verified; 26) with predetermined CA125 levels and twenty (20) healthy non-cancerous 135 subjects provided plasma samples for extracellular vesicle (EV) isolation, characterization, and 136 analyses. Patients were recruited at the CHUM from 1992 - 2012 and did not receive any neoadjuvant chemotherapy or radiotherapy. All patients were managed with primary surgery. 137 Gynecologic-oncologic pathologists examined all samples and assigned tumor grade and 138 139 histologic subtypes in accordance with the International Federation of Gynecology and 140 Obstetrics (FIGO) criteria. Computed Tomography imaging and CA125 levels during follow-ups were used to define disease-free survival (DFS; time of diagnosis to time of recurrence) and 141 overall survival (OS; time of diagnosis to time of death). Details of patient demographics and 142 clinical outcomes are outlined in Supplementary Table S1. 143

144

145 Interrogation of OVCA public datasets

Ovarian cancer public datasets were interrogated using <u>http://www.rocplot.org/ovarian/index</u> and <u>http://gepia.cancer-pku.cn/index.html</u> on 06/16/2022. The differential expressions (box plot; chemoresistance vs. chemosensitive) and test performances (ROC curves; chemoresistance prediction) of GSN, CTTN, ABCB1, MRP2, and RAB27A (n=958; sensitive=862; resistant=96; platinum) were investigated. Spearman's correlation tests were performed to assess the association between pGSN and the other genes. Significant correlations were inferred as $P \le$ 0.05.

153

154 **Reagents.**

Cis-diaminedichloroplatinum (CDDP), phenylmethylsulfonyl fluoride (PMSF), aprotinin, 155 156 dimethyl sulfoxide (DMSO), sodium orthovanadate (Na₃VO₄), CCK-8, and Hoechst 33258 were 157 supplied by Millipore Sigma (St. Louis, MO). Two preparations of pGSN siRNA (siRNA1 and 158 2) and scrambled sequence siRNA (control) were purchased from Integrated DNA Technology (Iowa, USA) and Dharmacon (Colorado, USA), respectively. Human recombinant plasma 159 gelsolin (hrpGSN) were synthesized and provided by Dr. Chia-Ching Chang, National Yang 160 Ming Chiao Tung University, Taiwan. pGSN cDNA and 3.1A vector plasmids were provided by 161 Dr. Dar-Bin Shieh, National Cheng Kung University Hospital, Taiwan. pCT-CD63-GFP was 162 purchased from System Biosciences, LLC. See Supplementary Table S2 for details on 163 antibodies and other reagents. 164

165

166 **Ovarian Cancer Cell Lines.**

Chemosensitive and chemoresistant OVCA cell lines (1.6 x 10^6 cells) of high grade serous 167 (HGS; TOV3041G, TOV3133 and OV90) and endometrioid (A2780s and A2780cp) histologic 168 169 subtypes were used for all in vitro studies. Dr. Anne-Marie Mes-Masson (CHUM, Montreal, Canada) generously donated the HGS cell lines whereas the endometioid cell lines were 170 generously donated by Dr. Barbara Vanderhyden (Ottawa Hospital Research Institute, Ottawa, 171 172 Canada). Quality control was performed to prevent any batch-to-batch changes on the morphology and growth rate. An addition, cell lines were regularly authenticated and tested for 173 *Mycoplasma* contamination using PlasmoTestTM Mycoplasma Detection kit (InvivoGen; catalog 174 number: rep-pt1). The HGS OVCA cells were maintained in OSE medium (wisent Inc. St-Bruno, 175 176 QC, Canada) supplemented with 10% FBS (Millipore Sigma; St. Louis, MO, USA), 250 µg/mL 177 amphotericin B, and 50 mg/mL gentamicin (wisent Inc. St-Bruno, QC, Canada). The

endometrioid OVCA cells were maintained in Gibco RPM1 1640 (Life Technologies, Grand
Island, NY, USA) supplemented with 10% FBS (Millipore Sigma; St. Louis, MO), 50 U/mL
penicillin, 50 U/mL streptomycin, and 2 mmol/L l-glutamine (Gibco Life Technologies, NY,
USA). All experiments were carried out in serum-free media. Details on the mutations of the cell
lines used are described in **Supplementary Table S3**.

183

184 pGSN Gene Interference.

185 Chemoresistant cells were transfected with siRNA (50 nM, 24 h; scramble as controls) and 186 sensitive cells transfected with cDNA (2 μ g; 24 h; empty vectors as controls) using 187 lipofectamine 2000, and were subsequently treated with CDDP (10 μ M; 24 h)) then harvested for 188 analysis as previously described (27-29). Two different siRNAs were used for each target to 189 exclude off-target effects. Western blot was used to confirm pGSN knock-down and over-190 expression (30). See **Supplementary Table S2** for details on antibodies and **Supplementary** 191 **Table S4** for customized siRNA oligonucleotide duplexes.

192

193 Extracellular Vesicle (EVs) Isolation and Characterization.

EVs were isolated and characterized from serum-free conditioned media from cultured cells as well as ovarian cancer patient plasma as described (31). Differential ultracentrifugation was used to isolate EVs from conditioned media while ExoQuick Ultra was used for the plasma samples. Conditioned media were centrifuged at 300 ×g (10 mins at RT) to remove cells and debris, 20,000 ×g (20 mins at RT) to remove large EVs (microparticles), and then at 100,000 ×g (90 mins at 4°C) to pellet sEVs. For plasma-derived EV isolation, 100 μ L of ExoQuick precipitation reagent is added to plasma (40 μ L in 500 μ L of 0.1 μ m filtered PBS) and incubated on ice for 30

mins. The content is then centrifuged at $3,000 \times g$ for 10 mins and the suspension discarded. The pellet is then re-suspended in a buffer (provided by the manufacturer), transferred into prewashed ExoQuick Ultra columns, and then centrifuged at $1,000 \times g$ for 30 secs. The receiving tube is then detached and EVs collected. EVs are then characterized using nanoparticle tracking analyses (particle size distribution and concentration), Western blot (EV-specific markers) and transmission electron microscopy (EV size and purity). Isolated EVs that were not used immediately were suspended in PBS and stored at -80°C for subsequent analyses.

208

209 Nanoparticle Tracking Analysis (NTA).

EVs diluted in PBS were analyzed, using the ZetaView PMX110 Multiple Parameter Particle Tracking Analyzer (Particle Metrix, Meerbusch, Germany) in size mode, and ZetaView software version 8.02.28, as previously described (31, 32). With 11 camera positions, EVs were captured at 21°C.

214

215 sEV-GFP tagging and uptake.

Chemosensitive and chemoresistant OVCA cell lines (1.6 x 10^6 cells) were transfected with exosome cyto-tracer, pCT-CD63-GFP (SBI System Biosciences; CYTO120-PA-1; 1 µg) in serum-free RPM1-1640 and then treated with CDDP (10 µM; 24 h). Cells were fixed and processed for confocal microscopy. Details on antibodies are described in **Supplementary Table S2**.

221

222 **Protein Extraction and Western blot Analysis.**

Western blotting (WB) procedure for proteins were carried out as described previously (27, 28, 30). After protein transfer, membranes were incubated with primary antibodies (1:1000) in 5% (wt/vol) blotto and subsequently with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (1:2000) in 5% (wt/vol) blotto. See **Supplementary Table S2** for details of antibodies used. Chemiluminescent Kit (Amersham Biosciences) was used to visualize the peroxidase activity. Signal intensities generated on the film were measured densitometrically using Image J.

230

231 Assessment of Cell Proliferation and Apoptosis.

Apoptosis and cell proliferation were assessed morphologically with Hoechst 33258 nuclear stain and colorimetrically with the CCK-8 assay, respectively. "Blinded" counting approach was used to prevent experimental bias with the Hoechst 33258 nuclear staining.

235

236 Transmission Electron Microscopy (TEM).

OVCA cell were pelleted (4000 × g; 20 min) and processed, as previously described (33). Resin
sections were stained with uranyl acetate and lead citrate solutions and examined with a Jeol
JEM 1230 transmission electron microscope (Akishima, Japan).

240

241 Immunoelectron Microscopy (iEM).

242 Cell pellets (4000 g; 20 min) were processed as previously described (33). The grids were

243 washed three times in PBST, immunostained with anti-pGSN antibody (Supplementary Table

S2), rinsed in distilled water, stained with uranyl acetate and lead citrate, and photographed with

a Jeol JEM 1230 transmission electron microscope (Akishima, Japan).

11

246 EDS and ICP-MS

247 Energy Dispersive Spectroscopy (EDS) was performed in High-Resolution Transmission 248 Electron Microscopy (HR-TEM, JEM-2010/JEOL Co. 200 KV) in NCKU for the quantitative analysis of elemental compositions and distributions in chemoresistant cells, particularly 249 250 platinum signal that represent the anti-cancer drug. The samples were dispersed in ethanol and 251 dropped onto a copper grid with an amorphous carbon film followed by evaporation of the 252 solvent in a vacuum desiccator. The elemental composition was detected and quantified by EDS. 253 In order to determine the Cisplatin content in the sEVs and in the condition medium, the Pt ion 254 present in the drug was analyzed by THERMO Element XR High-resolution ICP-mass 255 spectrometer (Element XR, Thermo Fisher Scientific, Bremen, Germany). Conditioned media 256 were collected and sEVs were isolated using differential ultra-centrifugation before analysis. The sEVs pellets were lysed with lysis buffer (1% Triton X-100, 0,1 M Tris-HCl pH 7.4, 0.1% SDS) 257 258 containing protease inhibitors (Sigma-Aldrich). Then, the sEVs lysates were digested by adding 259 200 µL or 50 µL of concentrated nitric acid (Optima Grade, Fisher Scientific, Cambridge, MA) and kept at at 60°C for 2 hours. The final digested solutions were diluted with deionized water 260 (DI Water). Indium (1 μ g/L) was added to the specimens as internal standard. The same matrix 261 262 (lysing solution, nitric acid) was used as the calibration standard for the external control. Cell 263 culture medium samples were diluted 1:100 with DI Water before performing the Pt analysis, adding only Indium as internal standard to minimize the effect of instrumental variation. The 264 265 levels of the drug into the medium were expressed as ng of Cisplatin per mL of the solution.

266

267 SERS quantification of sEV and CDDP

268 Cysteine capped gold nanoparticles were synthesized using the citrate reduction method to form particles from Au³⁺. After the particles had formed, they were washed via centrifugation and re-269 suspended in 10 mM NaOH with 1 µM cysteine. The amino acid preferentially bound to the gold 270 surfaces due to the formation of a gold-thiol bond. To analyse sEV samples, they were first 271 272 sonicated for 15 minutes to break-up the vesicles before mixing with the nanoparticles and 273 incubating overnight. Before Raman measurement NaCl was added to the sEV-nanoparticle mixture to initiate aggregation, and this process was measured by means of an in-house built 274 275 Raman spectrometer (785 nm excitation, 30 mW, 0.65 NA objective, Kaiser f/18i spectrograph, TE cooled Andor CCD). CDDP concentration could be inferred based on the aggregation rate of 276 277 the particles, with increasing drug concentration resulting in faster aggregation (26). The steady-278 state SERS spectrum contained the signature of the sEV components which had also bound to 279 the nanoparticles, and this spectrum could be used to quantify the sEVs in the sample using 280 multi-variate regression (26).

281

282 Statistical Analyses.

The SPSS software version 25 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism 7 (San 283 284 Diego, CA, USA) were used to perform all statistical analyses and two-sided P \leq 0.05 considered 285 to indicate statistical significance. Receiving operating characteristic (ROC) curves were used to assess the performances of sEV/CA125, sEV and CA125 over their entire range of values. The 286 area under the curve (AUC) was used as an index of global test performance. The association 287 between sEVs and CA125 was analysed using Pearson's correlation test (two-tailed). The means 288 289 of sEVs and sEV/CA125 levels were plotted against stage, residual disease, histological 290 subtypes, tumor recurrence, chemoresistance and survival using scatter plots and statistical

analyses performed by using unpaired *t*-test; Gaussian distribution was tested. The relationship of these dichotomous variables to other clinicopathologic correlates was examined using Fisher exact test, T test and Kruskal Wallis Test as appropriate. Survival curves (DFS and OS) were plotted with Kaplan Meier and P-values calculated using the log-rank test. Univariate and multivariate Cox proportional hazard models were used to assess the hazard ratio (HR) for CA125, pGSN, stage (FIGO), residual disease and age as well as corresponding 95% confidence intervals (CIs).

298

299 **RESULTS**

300 Extracellular vesicle isolation and characterizations from OVCA cell lines

301 To investigate the role of pGSN in EV-mediated secretion of CDDP in OVCA chemoresistance, 302 OVCA cell lines of HGS and Endometrioid subtypes were cultured with and without CDDP treatment (10 µM; 24 h) and their conditioned media were collected for EV isolation and 303 characterization. Conditioned media was filtered with 0.22um pore size filter and EVs isolated 304 305 using differential ultra-centrifugation (Fig. 1A). EVs were characterized using nanoparticle 306 tracking analyses to determine particle size distribution and concentration (Fig. 1B), immunegold electron microscopy to determine particle size, EV purity and gelsolin content (Fig. 1C). 307 308 Based on the particle isolation and characterizations, the EVs had an average size of 130 nm and were positive for CD63 and CD9 markers suggesting they are sEVs. Electron microscopy 309 confirmed that they contained secreted gelsolin (Fig. 1). SEVs from the plasma of OVCA 310 patients and non-OVCA subjects were isolated using ExoQuick ULTRA (System Biosciences), 311 312 which employs the use of a polymer for robust vesicle precipitation, low speed centrifugation,

and column filtration (Fig. 1D). SEVs were characterized using nanoparticle tracking analysis and Western blotting (Fig. 1E). Unlike the sEV-free plasma, the sEVs isolated from patients' plasma had an average median size of 136 nm and were positive for sEV markers (CD 9, CD63, and CD81) but negative for GM130, suggesting they are mainly sEVs (Fig. 1E and F). The presence of GAPDH also suggests the sEVs were intact (Fig. 1F).

318 Chemoresistant OVCA cells secrete higher sEV-CDDP and exhibit a lateral EV secretion 319 pattern

320 Chemosensitive (A2780s) and chemoresistant (A2780cp) cells were treated with or without CDDP (10 µM; 24 h) in a serum-free conditioned media (Fig. 2). The conditioned media was 321 collected and sEVs isolated. CDDP concentrations were determined in the sEVs as well as EV-322 323 free conditioned media using inductively coupled plasma reactive ion etching (ICP) (Fig. 2A). We observed that sEVs derived from chemoresistant cells contain significantly higher levels of 324 CDDP compared with that of chemosensitive cells (Fig. 2 A). Meanwhile, there were no 325 326 significant differences in the CDDP concentration detected in the serum-free conditioned media of both cells (Fig. 2A). The OVCA cells collected were processed for transmission and immune-327 328 gold electron microscopy (Fig. 2B-C). We observed a lateral or peripheral secretion of EVs in 329 more than 50% of the chemoresistant cells when treated with CDDP; a phenomenon that was not 330 seen in chemosensitive cells as well as non-treated chemoresistant cells (Fig. 2B). Colloidal gold granules labeling pGSN were also present in EVs (Fig. 2B). Interestingly, the conventional EV 331 secretion via multivesicular bodies and exocytosis were seen in chemoresistant cells not treated 332 with CDDP as well as the chemosensitive cells (Fig. 2C). We also assessed the platinum 333 distribution in the chemoresistant cells after CDDP treatment using energy dispersive x-ray 334 spectroscopy (EDS) (Fig. 2D). Cellular distribution of platinum was not significantly different 335

between chemoresistant cells treated with CDDP and those not treated (Fig. 2D), suggesting thatCDDP might have been exported via sEV secretion.

338 pGSN and CTTN are highly expressed in human chemoresistant OVCA tumors and their

339 protein contents in cell lines do not reduce upon CDDP treatment

sEV-mediated secretion of CDDP is a key determinant of OVCA chemoresistance; however, the 340 underlying mechanism is not known. Given pGSN has been shown to be a marker of 341 342 chemoresistance in OVCA as well as play a major role in EV biology; we investigated its 343 potential role in sEV-mediated OVCA chemoresistance. We interrogated string-db.org and found that while there was no interaction between pGSN and drug transport proteins (p-glycoprotein; 344 345 ABCB1 and ABCC2) as well as RAB27A, there was a potential interaction between pGSN and CTTN (Fig. 3A). We further interrogated the ovarian cancer TCGA public dataset 346 347 (http://gepia.cancer-pku.cn/index.html) on 06/16/2022 to assess the correlation (Spearman coefficient) between pGSN and CTTN, RAB27A, or ABCB1. We found that pGSN positively 348 correlated with CTTN and both proteins were significantly elevated in chemoresistant tumors 349 350 compared with chemosensitive tumors (Fig. 3B and Supp. Fig. S1). A positive correlation was 351 found between pGSN and MRP2, p-gp, and RAB27A (Supp. Fig. S1B-C). Additionally, we interrogated OV datasets (http://www.rocplot.org/ovarian/index) on 06/16/2022 to determine the 352 353 differential expression (box plot; chemoresistance vs. chemosensitive) and test performance (receiver operating characteristic (ROC) analysis; chemoresistance prediction) of GSN, CTTN, 354 ABCB1, MRP2, and RAB27A (Fig. 3B and Supp. Fig. S1) (n=958; sensitive=862; resistant=96). 355 356 All patients had serous tumors, had received platin-based treatment, and response was based on 357 progression free survival at 6 months. Using ROC analysis, we examined the test performance of pGSN (area under the curve (AUC)=0.56; p=0.03) and CTTN (AUC: 0.6; p<0.0001) and found 358

both markers are significantly predictive of OVCA chemoresistance (Fig. 3C). We observed that
P-glycoprotein but not MRP2 nor RAB27A are significantly predictive of chemoresistance in
human OVCA tumors (Supp. Fig. S1A).

362 To begin investigating the role of sEV-mediated chemoresistance in OVCA, chemosensitive 363 (A2780s, TOV3041G, TOV3133) and chemoresistant (A2780cp and OV90) OVCA cells were treated with or without CDDP (10 µM; 24 h) (Fig. 3D). pGSN, CTTN, P-gp, RAB27A and 364 GAPDH contents were assessed by Western blot. Cisplatin-induced cell death was analyzed by 365 Hoechst staining, and cell viability was verified by CCK-8 assay (Fig. 3D). pGSN and CTTN 366 367 contents were reduced by CDDP in the chemosensitive cells but not in the chemoresistant cells 368 (Fig. 3D). These results were independent of histologic subtype. Notably, pGSN content was 369 higher in chemoresistant compared to chemosensitive cells (Fig. 3D). P-glycoprotein and RAB27A contents were not detectable in the sensitive cells; however, weak signals were 370 371 observed in the chemoresistant cells (Fig. 3D). Also, CDDP-induced apoptosis was significantly 372 higher in the chemosensitive cells compared with the chemoresistant cells (Fig. 3D).

373 pGSN regulates sEV release of CDDP and chemoresponsiveness in OVCA cells

The role of pGSN in sEV-mediated release of CDDP was further investigated in OVCA cells. Gold nanoparticles (AuNP) were synthesized and capped with cysteine (Au-cys) as previously demonstrated and characterized. Due to the strong negative charge of Au-cys particles, they form a mono-stable colloid in the absence of sEVs containing CDDP (Fig. 4A and B). Upon the addition of sEV containing CDDP, the cysteine residues are attacked by CDDP resulting in the reduction of the surface charges of the Au-NP (Fig. 4A and B). This results in Au-NP-sEV-CDDP aggregation which could be measured by Surface Enhance Raman Spectroscopy (SERS);

a response that is proportional to the concentration of sEV and CDDP. Mono-stable colloid
 formation and aggregations of the particles were confirmed using transmission electron
 microscopy (Fig. 4B).

pGSN was silenced in chemoresistant cells using siRNAs (50 nM; 24 h; empty vector as a 384 385 control) (Fig. 4C) and overexpressed in chemosensitive cells using cDNA (2 µg; 24 h) and human recombinant pGSN (hrpGSN, 10 µM; 24 h) (Fig. 4D and Supp. Fig. S2A). pGSN, CTTN 386 and GAPDH contents were assessed by Western blot and CDDP-induced death analyzed by 387 Hoechst staining. sEVs were isolated and their levels together with sEV-CDDP concentrations 388 389 determined using SERS. pGSN knock-down resulted in the downregulation of CTTN content; a phenomenon that decreased sEV secretion as well as sEV-CDDP content (Fig. 4C and Supp. Fig. 390 S2B). Additionally, pGSN knock-down sensitized the chemoresistant cells to CDDP-induced 391 apoptosis (Fig. 4C). pGSN overexpression in chemosensitive cells increased CTTN content, sEV 392 393 secretion as well as sEV-CDDP content (Fig. 4D and Supp. Fig. S2C). pGSN overexpression 394 also suppressed CDDP-induced apoptosis in the chemosensitive cells (Fig. 4D). Additionally, we observed that hrpGSN promoted sEV secretion in chemosensitive cells; an observation which 395 396 was consistent with pGSN overexpression by cDNA (Fig. 4D).

The above findings potentially suggest that pGSN regulates CTTN expression, which leads to enhanced secretion of sEVs in chemoresistant OVCA cells. Also, pGSN is enriched with sulphur and metallic binding sites; properties that might facilitate its direct binding to platinum, leading to enhanced CDDP packaging in sEVs and eventual release from the cell (Fig. 4E).

401 SEV to CA125 ratio (sEV/CA125) is a strong predictor of stage 1 disease, 402 chemoresponsiveness and favorable survival outcomes in OVCA patients

403 After characterizing our biosensor in OVCA cell lines, we extended its application to measuring 404 SEV concentration in human patient plasma. Plasma samples were collected from 99 OVCA patients with HGS, LGS and unverified histologic subtypes (Supplementary Table S2). Plasma-405 406 derived sEVs from OVCA patients and non-OVCA subjects were isolated and characterized (Fig. 1). The biosensor application was tested with the buffers used in the sEV isolation to ensure 407 they do not interfere with the SERS measurement (Supp. Fig. S3A and B). Although the buffers 408 increased the aggregation of the nanogold particles, this could easily be normalized and did not 409 410 affect CDDP quantification (Supp. Fig. 3B and C). Mono-stable colloid formation and Au-NP 411 aggregation with the plasma-derived sEV were confirmed using transmission electron microscopy before SERS quantification was performed (Fig. 5A). 412

The sEV concentration and EV/CA125 ratio were determined and their mean±SD values 413 correlated with patient clinical outcomes (stage, tumor recurrence, survival, chemoresistance, 414 415 and residual disease) (Figs. 5, 6 and Supp. Fig. S4). We observed that patients with advanced 416 stages of OVCA had levels of sEVs comparable to those in early stages (Fig. 5B); however, no 417 significant difference in sEV concentrations was observed among the patients and the control 418 healthy individuals. There's also no correlation detected with the presence of residual disease (RD<1cm vs, RD>1cm), chemoresistance (PFI<6mo vs. PFI>6mo), tumor recurrence (yes vs. 419 no), and the level of CA125 (low vs. high) (Supp. Fig. S4A). SEVs had a negative correlation 420 with CA125, hence we developed a ratio with both markers to investigate their clinical utility 421 422 (Supp. Fig. S4B). SEV/CA125 ratio had better clinical utility compared to sEV and CA125 concentrations alone with regards to OVCA stage, tumor recurrence and disease state (Fig. 5C). 423 424 However, a trend (although not significant) was observed with residual disease and histologic differentiation subtypes (Supp. Fig. S4C). Using ROC analysis, we determined the test 425

426 performances of sEV, sEV/CA125, and CA125 in predicting patient clinical outcomes (Fig. 5D). 427 We found that sEV/CA125 was the most robust in predicting stage 1 disease, non-recurrence, patient survival, chemoresponsiveness and optimal residual disease in OVCA patients (Fig. 5D). 428 Kaplan-Meier survival curves with dichotomized sEV/CA125 ratio (low vs. high, cut-off = 68.8) 429 430 and log rank test were used to compare the survival distributions between the groups (Fig. 6A). We observed that patients with high sEV/CA125 had significantly improved disease free survival 431 (DFS; 63 months vs. 18 months, p=0.018) as well as overall survival (OS; 83 months vs. 48 432 months, p=0.037) compared with patients with low sEV/CA125 (Fig. 6A). We further 433 434 investigated if sEV/CA125 could be used to predict multiple clinical outcomes using a heat map 435 (Fig. 6B-C). Compared with sEV and CA125 individually, sEV/CA125 ratio provided a 436 significant prediction value for multiple clinical outcomes. Patients with increased sEV/CA125 were mostly in stage 1 and did not develop recurrence or resistance to treatment (Fig. 6B and C). 437 438 SEV and CA125 concentrations alone were not predictive of clinical outcomes.

439

440 **DISCUSSION**

For the first time, we have shown evidence that pGSN plays a regulatory role in sEV secretion as well as sEV-mediated release of CDDP; factors that are involved in OVCA chemoresistance. Additionally, we extended the application of our novel sEV-based biosensor to a small OVCA patient cohort to develop a highly sensitive diagnostic platform for the detection of early stage OVCA and prediction of chemoresponsiveness.

446 Drug efflux is a key determinant of chemoresistance in a lot cancer types, including OVCA
447 cancer (34-37). Most studies have identified multi-drug resistant proteins such as p-glycoprotein

448 to be responsible for drug efflux in cancer cells, thus rendering chemotherapeutic agents unable 449 to induce death in cancer cells (36, 37). In this present study, we have demonstrated that sEVs 450 serve as a vehicle for exporting chemotherapeutic agents from OVCA cancer cells rather than 451 using drug transport channels. Chemoresistant OVCA cells treated with CDDP secreted increased amount of sEVs as well as sEV containing CDDP compared with their sensitive 452 counterparts. This could potentially explain why targeting drug transport channels such as P-453 454 glycoprotein has not yielded any therapeutic benefit in OVCA given the sEVs role in drug efflux. 455 This suggests that sEV secretion is a potential therapeutic target to tackle chemoresistance in OVCA. 456

Targeting sEV secretion also demands understating the mechanism underlying why 457 458 chemoresistant cells secrete more sEVs and sEV-CDDP. pGSN is overexpressed in chemoresistant OVCA compared with chemosensitive cells and transported via sEVs (10). The 459 460 positive association between pGSN and sEVs made us investigate the role of pGSN in sEV secretion. We observed that silencing pGSN reduced the expression of CTTN (involved is sEV 461 462 release mechanisms) in chemoresistant cells resulting in decreased sEV secretion and EV-CDDP 463 release. The opposite happened when pGSN was overexpressed in chemosensitive OVCA cells. Targeting pGSN in the chemoresistant cells resulted in increased accumulation of CDDP leading 464 to increased apoptosis, suggesting that pGSN is a key regulator of CTTN expression. These 465 findings are consistent with the study in which pGSN and CTTN were found to be upregulated 466 and co-localized in resistant pancreatic cancer cell lines. Furthermore, recent studies have shown 467 that proteins rich in sulphur and amines have high affinity for cisplatin binding. Since pGSN has 468 469 these properties as well as more than 10 metal binding sites, there is a possibility that it could

directly bind to CDDP and facilitate their packaging into sEVs for secretion. This will be worthinvestigating in the future.

Late diagnosis is a huge challenge to therapeutic success and patient survival. Developing a highly sensitive diagnostic platform for early OVCA diagnosis is of urgent need. With heterogeneity and protein interference as major challenges when using SERS for sEV analysis, we have developed a biosensor to overcome this challenge. This biosensor is able to react with sEVs and CDDP simultaneously; a strategy that enables us to quantitate both sEVs and CDDP simultaneously using SERS. This strategy is highly sensitive and superior to other studies that have developed gold nanoparticles for sEV analysis alone.

We examined the diagnostic utility of our sEV-based biosensor in a small pre-operative OVCA 479 480 cohort. Although sEVs could be detected and quantified, their diagnostic value was not as strong 481 as when combined with CA125. This could potentially be due to the fact that the biosensor recognized sEVs from origins other than OVCA. To overcome this, we used a ratio of sEVs to 482 483 CA125. We observed that the sEV/CA125 ratio had a significantly improved diagnostic value. sEV/CA125 was significantly elevated in stage 1 patients compared to stages 2-4 and 484 485 outperformed CA125 and sEV in identifying stage 1 disease. This is a promising marker given 486 conventional biomarkers have only provided modest diagnostic value. Interestingly, sEV/CA125 487 also outperformed CA125 and sEVs in predicting tumor recurrence, chemoresistance, residual disease and patient survival. This is exciting given there is no reliable biomarker to predict tumor 488 489 recurrence and chemoresistance. OVCA patients with increased sEV/CA125 had prolonged 490 survival compared with those with low sEV/CA125, suggesting that sEV/CA125 could be used 491 as a potential marker for early stage OVCA and predict patient survival outcomes prior treatment or surgery. With limited biomarker options for early stage OVCA and prediction of 492

493 chemoresistance, sEV/CA125 could be further investigated to provide the needed diagnostic494 tool.

495

496 CONCLUSION

We have demonstrated that pGSN regulates sEV and sEV-CDDP secretions via CTTN upregulation leading to decreased intracellular CDDP accumulation and apoptosis. These processes further suppress chemo-responsiveness in OVCA cells. Additionally, we have applied a novel biosensor to develop a platform that is effective in identifying stage 1 disease and predicting tumor recurrence and chemoresistance. Although these findings are promising and have an important clinical relevance, further validation of the platform is needed in a larger patient cohort and animal models.

504 **REFERENCES**

505 1. Release notice - Canadian Cancer Statistics 2019. Health Promot Chronic Dis Prev Can. 506 2019;39(8-9):255.

507 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 508 2018;68(1):7-30.

509 3. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer 510 statistics, 2018. CA: a cancer journal for clinicians. 2018;68(4):284-96.

511 4. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing 512 recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164-74.

513 5. Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, et al. HE4, CA125 and risk 514 of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic 515 mass: An Italian multicenter study. Gynecologic oncology. 2016;141(2):303-11.

516 6. Nowak M, Janas L, Stachowiak G, Stetkiewicz T, Wilczynski JR. Current clinical application of 517 serum biomarkers to detect ovarian cancer. Przeglad menopauzalny = Menopause review. 518 2015;14(4):254-9.

519 7. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. Plasma and cytoplasmic
520 gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature.
521 1986;323(6087):455-8.

522 8. Yin HL, Kwiatkowski DJ, Mole JE, Cole FS. Structure and biosynthesis of cytoplasmic and secreted 523 variants of gelsolin. The Journal of biological chemistry. 1984;259(8):5271-6.

524 9. Feldt J, Schicht M, Garreis F, Welss J, Schneider UW, Paulsen F. Structure, regulation and related 525 diseases of the actin-binding protein gelsolin. Expert reviews in molecular medicine. 2019;20:e7.

526 10. Asare-Werehene M, Nakka K, Reunov A, Chiu CT, Lee WT, Abedini MR, et al. The exosome-527 mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. 528 Oncogene. 2020;39(7):1600-16.

Ma X, Sun W, Shen J, Hua Y, Yin F, Sun M, et al. Gelsolin promotes cell growth and invasion
through the upregulation of p-AKT and p-P38 pathway in osteosarcoma. Tumour biology : the journal of
the International Society for Oncodevelopmental Biology and Medicine. 2016;37(6):7165-74.

- 532 12. Wang PW, Abedini MR, Yang LX, Ding AA, Figeys D, Chang JY, et al. Gelsolin regulates cisplatin 533 sensitivity in human head-and-neck cancer. International journal of cancer Journal international du 534 cancer. 2014;135(12):2760-9.
- 535 13. Tsai MH, Wu CC, Peng PH, Liang Y, Hsiao YC, Chien KY, et al. Identification of secretory gelsolin 536 as a plasma biomarker associated with distant organ metastasis of colorectal cancer. Journal of 537 molecular medicine (Berlin, Germany). 2012;90(2):187-200.

538 14. Xu Y, Zhang Y, Wang L, Zhao R, Qiao Y, Han D, et al. miR-200a targets Gelsolin: A novel
539 mechanism regulating secretion of microvesicles in hepatocellular carcinoma cells. Oncology reports.
540 2017;37(5):2711-9.

541 15. Asare-Werehene M, Tsuyoshi H, Zhang H, Salehi R, Chang CY, Carmona E, et al. Plasma Gelsolin
542 Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of
543 Macrophage Subtypes. Cancers. 2022;14(4).

54416.Asare-Werehene M, Communal L, Carmona E, Han Y, Song YS, Burger D, et al. Plasma Gelsolin545Inhibits CD8(+) T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in546Ovarian Cancer. Cancer research. 2020;80(18):3959-71.

54717.Chen CC, Chiou SH, Yang CL, Chow KC, Lin TY, Chang HW, et al. Secreted gelsolin desensitizes548and induces apoptosis of infiltrated lymphocytes in prostate cancer. Oncotarget. 2017;8(44):77152-67.

54918.Giampazolias E, Schulz O, Lim KHJ, Rogers NC, Chakravarty P, Srinivasan N, et al. Secreted550gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell. 2021;184(15):4016-55131.e22.

55219.Whitham M, Parker BL, Friedrichsen M, Hingst JR, Hjorth M, Hughes WE, et al. Extracellular553Vesicles Provide a Means for Tissue Crosstalk during Exercise. Cell metabolism. 2018;27(1):237-51.e4.

554 20. Budnik V, Ruiz-Canada C, Wendler F. Extracellular vesicles round off communication in the 555 nervous system. Nature reviews Neuroscience. 2016;17(3):160-72.

556 21. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to 557 immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382-6.

558 22. Wang Q, Lu Q. Plasma membrane-derived extracellular microvesicles mediate non-canonical 559 intercellular NOTCH signaling. Nature communications. 2017;8(1):709.

56023.Marimpietri D, Airoldi I, Faini AC, Malavasi F, Morandi F. The Role of Extracellular Vesicles in the561Progression of Human Neuroblastoma. International journal of molecular sciences. 2021;22(8).

562 24. Jermyn M, Mercier J, Aubertin K, Desroches J, Urmey K, Karamchandiani J, et al. Highly Accurate 563 Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy. Cancer 564 research. 2017;77(14):3942-50.

565 25. Paidi SK, Rizwan A, Zheng C, Cheng M, Glunde K, Barman I. Label-Free Raman Spectroscopy 566 Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer. Cancer research. 567 2017;77(2):247-56.

568 26. Robert A. Hunter MA-W, Aseel Mandour, Benjamin K. Tsang and Hanan Anis. Determination of 569 Chemoresistance in Ovarian Cancer by Simultaneous Quantification of Exosomes and Exosomal Cisplatin

with Surface Enhanced Raman Scattering. Sensors and Actuators: B Chemical. 2022;354(131237).

571 27. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in 572 chemoresistant ovarian cancer cells in vitro. Oncogene. 2004;23(42):6997-7004.

573 28. Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK. Akt promotes chemoresistance in human 574 ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like 575 inhibitory protein. Oncogene. 2010;29(1):11-25.

57629.Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in577ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene.5782012;31(17):2175-86.

- 579 30. Abedini MR, Wang PW, Huang YF, Cao M, Chou CY, Shieh DB, et al. Cell fate regulation by 580 gelsolin in human gynecologic cancers. Proceedings of the National Academy of Sciences of the United 581 States of America. 2014;111(40):14442-7.
- 582 31. Burger D, Vinas JL, Akbari S, Dehak H, Knoll W, Gutsol A, et al. Human endothelial colony-583 forming cells protect against acute kidney injury: role of exosomes. The American journal of pathology. 584 2015;185(8):2309-23.
- 585 32. Vinas JL, Burger D, Zimpelmann J, Haneef R, Knoll W, Campbell P, et al. Transfer of microRNA-586 486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury. 587 Kidney international. 2016;90(6):1238-50.
- 588 33. Reunov A, Pimenova E, Reunova Y, Menchinskaiya E, Lapshina L, Aminin D. The study of the 589 calpain and caspase-1 expression in ultrastructural dynamics of Ehrlich ascites carcinoma necrosis. Gene. 590 2018;658:1-9.
- 591 34. Mo L, Pospichalova V, Huang Z, Murphy SK, Payne S, Wang F, et al. Ascites Increases 592 Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. PLoS One. 593 2015;10(7):e0131579.
- 59435.Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism595and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum596complex and its biological significance. The Journal of biological chemistry. 1993;268(27):20116-25.
- 59736.Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ. Multidrug598resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent599drug efflux. Molecular pharmacology. 2006;69(4):1499-505.
- 60037.Tiwari AK, Sodani K, Dai CL, Ashby CR, Jr., Chen ZS. Revisiting the ABCs of multidrug resistance in601cancer chemotherapy. Current pharmaceutical biotechnology. 2011;12(4):570-94.
- 602
- 603
- 604
- 605
- 606

607

608 FIGURE LEGENDS



609

Figure 1: Extracellular vesicle (EVs) isolation and characterization. (A) Conditioned media form cultured OVCA cells were collected and filtered using 0.22 um filter. Differential ultracentrifugation was used to isolate small EVs after which they were characterized using (B) nanoparticle tracking analyses (NTA; particle size distribution and concentration) and (C) electron microscopy (EM). (D) Small EVs were isolated from the plasma of human OVCA

patients (n=99) and non-OVCA subjects (n=20) using Exoquick Ultra technique. EVs were then
characterized using (E) nanoparticle tracking device (size distribution) and (F) Western blot
analyses (small EV markers; CD9, CD63, CD81, negative marker; GM130, vesicle integrity
marker; GAPDH).

619



	Element At%	c	N	s	6
Spectrum 27	Spot 31	88.1	5.5	0.1	0
	Spot 32	89.7	5.4	0.1	0
Secture 35	Spot 33	88.6	4.4	0.2	0
+ Spectrum 30 Spectrum 36	Spot 34	89.6	2.9	0.1	0.1
	Spot 35	87.8	4.4	0.1	0
Curra 2	Spot 36	94.2	1.4	0	0
Spectrum 24	Spot 37	83.6	6.5	0.1	0
Spectrum 39	Spot 38	92.1	7.4	0	0
-Spectrum 33	Spot 39	92.1	7.4	0.1	0
	Spot 40	91.0	0	0.1	0

620

621

622

Spot 10

Spot 11

Spot 12

Spot 13

Spot 14

Spot 15

Spot 16

Spot 17

Spot 18

Spot 19

90.8

89.9

91.1

88.3

93.5

89.9

84.5

92.7

93.7

99.8

1.9

1.8

1.4

0.1

4.5

0.7

1.1

Q

0

0

0.2

0.2

0

ō

0.2

0.1

0

Q

0

0

0.1

0.2

0.1

0.1

0

0.1

0.1

0.1

0.1

0.2

Figure 2: Chemoresistance OVCA cells secrete higher sEV-CDDP and exhibit abnormal 623 EV secretion pattern. (A) sEV-CDDP content is higher in chemoresistant cells compared with 624 chemosensitive cells. Chemosensitive (A2780s) and chemoresistant (A2780cp) were cultured 625 626 and treated with or without CDDP (10 um; 24 h). Conditioned media were collected and sEVs 627 isolated using differential ultra-centrifugation. CDDP content in the sEVs and conditioned media was analyzed using inductively coupled plasma reactive ion etching (ICP). (B and C) 628 629 Chemoresistance OVCA cells when treated with CDDP exhibits peripheral secretion of sEVs 630 which is not found in untreated chemoresistant cells. Chemoresistance OVCA cells were treated with or without CDDP (10 uM; 24 h). Cells were processed and sEV secretion analyzed using 631 transmission and immuno-gold electron microscopy (As0; A2780s without treatment, As10; 632 A2780s treated with 10 µM CDDP, Cp0; A2780cp without treatment and Cp10; A2780cp treated 633 634 with 10 µM CDDP. (D) Platinum (Pt), calcium (C), nitrogen (N) and Sulphur (S) distribution 635 within chemoresistant cells were analyzed using energy dispersive x-ray spectroscopy (EDS). 636 637 638 639 640

- 641
- 642
- 643



644

Figure 3: pGSN and CTTN are highly expressed in chemoresistant OVCA patient tumors and their protein contents in cell lines do not reduce upon CDDP treatment. (A) Using string-db.org, we found a strong interaction between pGSN and CTTN but not ABCB1 (p-gp), ABCC2, RAB27A. (B – C) Our investigation of TCGA public dataset revealed that pGSN positively correlates with CTTN expression and both proteins are highly elevated in chemoresistant OVCA patients (n=958). The test performances of pGSN and CTTN were

651	evaluated using ROC curves and significant predictions were observed. (D) Chemosensitive
652	(A2780s, TOV3041G, TOV3133) and chemoresistant (A2780cp and OV90) cells were treated
653	with or without CDDP (10 uM; 24 h). pGSN, CTTN, P-gp, RAB27A and GAPDH contents were
654	assessed by Western blot. Cisplatin-induced cell death was analysed by Hoechst staining and
655	CCK-8 assay. Results are expressed as means ± SD from three independent replicate
656	experiments. [D, (a; **P<0.01 vs b, a; ***P<0.001 vs c)].
657	
658	
659	
660	
661	
662	
663	
664	
665	
666	
667	
668	
669	





Figure 4: pGSN regulates sEV release of CDDP and chemoresponsiveness. pGSN downregulation in chemoresistant cells reduced CTTN content, sEV production and sEV-CDDP release whereas the vice-versa occurs when pGSN in over-expressed in chemosensitive cells. (A) Negatively charged cysteine capped gold particles (AuNP) react with CDDP and sEVs to form aggregates which is used for the SERS quantification. The rate of aggregation is proportional to the concentrations of CDDP and sEV. (B). Transmission electron microscope (TEM) images of

689	mono-stable colloid of AuNP (without sEVs; left panel) and aggregated cysteine capped AuNP
690	(with sEVs and CDDP; right panel). The biological components in the solution did not appear
691	visible in the TEM images. pGSN was (C) silenced in chemoresistant cells (siRNA; 50 nM, 24 h)
692	and (D) over-expressed in chemosensitive cells (cDNA; 2 ug, rhpGSN; 10 uM; 24 h). Cells were
693	then treated with or without CDDP (10 uM; 24 h). pGSN, CTTN and GAPDH contents were
694	assessed by Western blot and cisplatin-induced cell death analysed by Hoechst staining. sEV and
695	CDDP concentrations were determined by biosensor aggregation using Raman spectroscopy. (E)
696	A hypothetical model suggesting the role of pGSN in the sEV release of CDDP from
697	chemoresistant OVCA cells. Results are expressed as means \pm SD from three independent
698	replicate experiments. [A - C, (a; **P<0.01 vs b)].
699	
700	
701	
702	
703	
704	
705	

706



Figure 5: sEVCA125 predicts stage 1 and tumor recurrence with high test accuracy. (A) Transmission electron microscope (TEM) images of mono-stable colloid of AuNP (without plasma-derived sEVs; left panel) and aggregated cysteine capped AuNP (with plasma-derived sEVs; right panel). The biological components in the solution did not appear visible in the TEM images. SEVs were isolated from the plasma of human OVCA patient with pre-determined

713	CA125, sEV or sEV/CA125 were correlated with patient clinical outcomes. (B) The mean levels
714	of sEV concentrations were compared between early $(I + II)$ and late $(III + IV)$ stages as well as
715	stage I and >stage 1 groups. Patients with late stage OVCA had lower levels of sEV
716	concentration compared with early stage or stage 1 patients. (C) The mean levels of sEV/CA125
717	were correlated with OVCA clinical outcomes (stages, tumor recurrence and survival). (D) The
718	test performances of sEV, sEV/CA125 and CA125 in the prediction of stage 1, tumor recurrence,
719	survival, chemoresistance and residual disease were compared using ROC curves.
720	
721	
722	
723	
724	
725	
726	
727	
728	
729	



730

Figure 6: High levels of sEV/CA125 provide favorable survival outcomes to OVCA patients. sEV/CA125 levels in OVCA patients (N=99) were correlated with progression-free survival (PFS) and overall survival (OS). Kaplan-Meier survival curves with dichotomized sEV/CA125 levels (low and high groups, cut-off = 68.8) and log rank test were used to compare the survival distributions between the groups. N = number of patients (B) sEV/CA125 predicts more than one clinical outcome of OVCA. SEV/CA125, sEV and CA125 were used in a heat map analyses to predict stage 1 and tumor recurrence as well as stage 1 and chemoresistance.

738